PDF(Pubmed)
Abstract：
Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. These drugs are safe, but temporary iatrogenic hypereosinophilia may sometimes be associated with clinical symptoms or organ damage. Here, we describe a case of severe hypereosinophilia in a patient with chronic rhinosinusitis with nasal polyps and asthma treated with dupilumab and a subsequent therapeutic shift to mepolizumab that led to maintenance of symptom control and concomitant normalization of blood eosinophil count.
摘要：
由于不同免疫途径的复杂激活，2型炎症是一种异质性疾病。评估生物制剂对慢性鼻窦炎伴鼻息肉和哮喘的疗效的研究进展迅速，导致有效的治疗选择的可用性。这些药物是安全的,但暂时性医源性嗜酸性粒细胞增多有时可能与临床症状或器官损伤有关。这里,我们描述了1例慢性鼻-鼻窦炎伴鼻息肉和哮喘患者的严重嗜酸性粒细胞增多症患者接受dupilumab治疗,随后治疗转向美泊利单抗,导致症状控制得以维持,同时血液嗜酸性粒细胞计数恢复正常.
